ArticleAlzheimer's research & therapy2013
Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease.
Article in Alzheimer's research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effect of acupuncture on brain regions modulation of mild cognitive impairment: A meta-analysis of functional magnetic resonance imaging studies.Frontiers in aging neuroscience · 2022Pooled it
- Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.Journal of neural transmission (Vienna, Austria : 1996) · 2019Pooled it
- Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.Alzheimer's research & therapy · 2016Pooled it
- Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.JAMA neurology · 2015Trial
- Addressing Disparities in Alzheimer's Disease-Related Healthcare Through Understanding Factors Contributing to Perceived Vulnerability Among Latinos in Northern Manhattan: A Qualitative Report.Journal of racial and ethnic health disparities · 2026Article
- Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges.The journal of prevention of Alzheimer's disease · 2025Review
- Detecting early stages of Alzheimer's disease using a web-based cognitive battery.GeroScience · 2025Article
- Memory screening in the community: Facilitating earlier dementia diagnosis and care-Preliminary data.Journal of the American Geriatrics Society · 2025Article
- Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing.Neurology · 2024Article
- Validation of the "Perceptions Regarding pRE-Symptomatic Alzheimer's Disease Screening" (PRE-ADS) Questionnaire in the German Population: Attitudes, Motivations, and Barriers to Pre-Symptomatic Dementia Screening.Journal of Alzheimer's disease : JAD · 2024Article
- Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial.The journal of prevention of Alzheimer's disease · 2024Article
- Attitudes of Family Members and Caregivers Regarding Alzheimer's Disease Pre-Symptomatic Screening.Journal of Alzheimer's disease reports · 2024Article
- Biomarkers of aging.Science China. Life sciences · 2023Review
- US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.The journal of prevention of Alzheimer's disease · 2023Article
- Attitudes toward pre-symptomatic screening for Alzheimer's dementia in five European countries: a comparison of family members of people with Alzheimer's dementiaFrontiers in genetics · 2023Article
- Disclosure of Genetic Risk Factors for Alzheimer's Disease to Cognitively Healthy Individuals-From Current Practice towards a Personalised Medicine Scenario.Biomedicines · 2022Review
- Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- People's interest in brain health testing: Findings from an international, online cross-sectional survey.Frontiers in public health · 2022Article
- Knowledge and Attitudes of two Latino Groups about Alzheimer Disease: a Qualitative Study.Journal of cross-cultural gerontology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionResearch is underway to develop an early medical test for Alzheimer's disease (AD).
methodsTo evaluate potential demand for such a test, we conducted a cross-sectional telephone survey of 2,678 randomly selected adults across the United States and four European countries.
resultsMost surveyed adults (67%) reported that they are "somewhat" or "very likely" to get an early medical test if one becomes available in the future. Interest was higher among those worried about developing AD, those with an immediate blood relative with AD, and those who have served as caregivers for AD patients. Older respondents and those living in Spain and Poland also exhibited greater interest in testing. Knowing AD is a fatal condition did not influence demand for testing, except among those with an immediate blood relative with the disease.
conclusionsPotential demand for early medical testing for AD could be high. A predictive test could not only advance medical research, it could transform political and legal landscapes by creating a large constituency of asymptomatic, diagnosed adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.